A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. - Paller AS; Siegfried EC; Simpson EL; Cork MJ; Lockshin B; Kosloski MP; Kamal MA; Davis JD; Sun X; Pirozzi G; Graham NMH; Gadkari A; et al. (Journal of the European Academy of Dermatology and Venereology : JEADV, 2021)